HRMY Relative Valuation
HRMY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HRMY is overvalued; if below, it's undervalued.
Historical Valuation
Harmony Biosciences Holdings Inc (HRMY) is now in the Fair zone, suggesting that its current forward PE ratio of 10.47 is considered Fairly compared with the five-year average of 23.82. The fair price of Harmony Biosciences Holdings Inc (HRMY) is between 9.12 to 130.92 according to relative valuation methord.
Relative Value
Fair Zone
9.12-130.92
Current Price：34.00
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.73
P/B
Median3y
4.97
Median5y
9.06
11.23
FCF Yield
Median3y
9.16
Median5y
6.29
Competitors Valuation Multiple
The average P/S ratio for HRMY's competitors is 1.57, providing a benchmark for relative valuation. Harmony Biosciences Holdings Inc Corp (HRMY) exhibits a P/S ratio of 2.25, which is 43.96% above the industry average. Given its robust revenue growth of 19.48%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Harmony Biosciences Holdings Inc (HRMY) currently overvalued or undervalued?
What is Harmony Biosciences Holdings Inc (HRMY) fair value?
How does HRMY's valuation metrics compare to the industry average?
What is the current P/B ratio for Harmony Biosciences Holdings Inc (HRMY) as of Jul 13 2025?
What is the current FCF Yield for Harmony Biosciences Holdings Inc (HRMY) as of Jul 13 2025?
What is the current Forward P/E ratio for Harmony Biosciences Holdings Inc (HRMY) as of Jul 13 2025?